Skip to main content
. Author manuscript; available in PMC: 2019 Oct 17.
Published in final edited form as: ACS Appl Mater Interfaces. 2019 Apr 2;11(15):13973–13983. doi: 10.1021/acsami.9b01406

Figure 4.

Figure 4

NanoVilli Chips combined with RT-ddPCR analysis can be used to detect and to monitor ROS1 rearrangements or acquired EGFR T790M mutation in tumor-derived EVs purified from NSCLC patients’ blood. (a) Dynamic change (0–75 days) of the ROS1 rearrangements observed for patient R07 with CD74-ROS1 rearrangement before and after crizotinib treatment. (b) Chest CT scans taken at days 0, 30, 75 post-crizotinib treatment. (c) Dynamic changes (0–279 days) of EGFR T790M mutation observed for patient E04 before and after osimertinib treatment. (d) Chest CT images were taken at day 0 (following response to gefitinib treatment), day 133 (disease relapse), and day 279 (post-treatment with osimertinib).